Search
Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of MM
- Nammi Therapeutics
- Jun 13, 2022
- 1 min read
FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of multiple myeloma. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.
Recent Posts
See AllNammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...
Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...
Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...
Commentaires